Jason Ryan Sells Shares of GeneDx Holdings Corp.

Jason Ryan sold 3,576 shares of GeneDx Holdings Corp. on June 18, 2026. This transaction was not part of a pre-arranged plan. Shares of GeneDx traded near $55.42 on Wednesday, June 18.

Insider Buying and Selling at GeneDx Holdings Corp.

Jason Ryan was not the only insider trading GeneDx shares recently. On the same day, Joshua Ruch sold 3,576 shares, while also purchasing 4,248 shares. Eli Casdin, Thomas Fuchs, and Keith Meister each bought 4,248 shares, while Meister also sold 3,576 shares.

Other Institutional Activity in GeneDx Holdings

Several major funds have adjusted their positions in GeneDx Holdings. Ark Investment Management LLC significantly increased its holdings by 720,022 shares, now holding 1,324,583 shares valued at approximately $85.1 million, marking a 119.1% increase. Westfield Capital Management Co LP also expanded its stake by 350,847 shares, ending with 1,369,108 shares worth about $87.9 million, a 34.5% increase. Meanwhile, Corvex Management LP grew its holdings by 169,520 shares, reaching 3,228,149 shares valued at $207.3 million, a 5.5% increase. In contrast, BlackRock, Inc. trimmed its position by 9,386 shares, now holding 1,550,708 shares worth around $99.6 million, a 0.6% decrease.

GeneDx Holdings Corp. Stock Down 6.1%

Shares of NasdaqGS:WGS were trading near $55.42 on Wednesday. GeneDx Holdings Corp. has a market cap of approximately $1.65 billion and a forward P/E ratio of 45.0. The stock has a 52-week low of $32.21 and a high of $170.87. Its 50-day moving average is $54.79, and the 200-day average is $99.42. The company maintains a healthy current ratio of 3.09 and a quick ratio of 2.83, with a debt-to-equity ratio of 66.19.

Recent Earnings

GeneDx Holdings reported revenue of $442.7 million, with a growth rate of 17.4%. Despite this, the company recorded a net margin of -17.6% and a return on equity of -30.4%. The next earnings report is expected on July 28, 2026.

Analysts Set New Price Targets

On June 23, 2026, Piper Sandler maintained its "buy" rating on GeneDx Holdings, setting a price target of $63.0. Other analysts, including Canaccord Genuity and Wells Fargo, also maintained "buy" ratings with targets of $75.0, demonstrating a strong consensus. The overall analyst consensus is a "strong buy" with an average target price of $77.0 from nine opinions.

About GeneDx Holdings Corp.

GeneDx Holdings Corp., based in Stamford, Connecticut, is a genomics company specializing in genetic testing services. The company focuses on pediatric and rare disease diagnostics through whole exome and genome sequencing. It also provides data and information services, developing an AI-based platform for sequencing analysis and reporting. GeneDx was founded in 2000 and employs about 1,300 people under the leadership of CEO Kevin Feeley.

Bottom Line

Jason Ryan's recent sale of GeneDx shares is a part of ongoing insider activity at the company. Investors closely watch such transactions for insights into executive sentiment. While GeneDx's recent financial performance shows some challenges, the company's focus on genomics and diagnostics remains a compelling narrative. Institutional investors have shown varied interest, with some increasing and others trimming their stakes. As always, remember that insider and institutional trades are backward-looking and may not reflect current sentiment.